Company profile: Rubicon Genomics

1.1 - Company Overview

Rubicon Genomics

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of advances in translating human genetics “laboratory knowledge” into practical medicine applications; founded in 2000 by University of Michigan faculty Dr. John Langmore and Dr. Vladimir Makarov, with roots in Michigan.

Products and services

🔒

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Rubicon Genomics

Ginkgo Bioworks

HQ: United States Website

Description: Provider of biological engineering products and custom microbes, designing, engineering, developing, testing, and licensing organisms. Discovers molecules for flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals, and provides probiotic bacteria.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Ginkgo Bioworks company profile →

Syros

HQ: United States Website

Description: Provider of a gene control platform that systematically analyzes regulatory regions of the genome to develop small-molecule medicines that control gene expression, and developer of oral therapeutics including tamibarotene (selective RARα agonist) in clinical development for genomically defined HR-MDS and AML, and previously clinical assets SY-2101 (oral arsenic trioxide for APL) and SY-5609 (CDK7 inhibitor for pancreatic cancer).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Syros company profile →

Floragenex

HQ: United States Website

Description: Provider of innovative genomic analysis solutions for human, plant, and animal systems. Oregon-based privately owned biotechnology company delivering results in hundreds of genomics studies since 2007, supporting research in genetics, ecology, evolutionary biology, and biomedical fields.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Floragenex company profile →

4D Path

HQ: United States Website

Description: Provider of H&E biopsy/resection image analysis, including 4D Q-Plasia OncoReader Breast (software-as-a-medical-device) for diagnostic accuracy in breast cancer and 4D Q-Plasia OncoReader Pan-Cancer, a cloud platform identifying cancer type, molecular subtypes, grades, and molecular profiles. Also offers automated detection and prognostic evaluation from H&E whole slide images and biomarker profiling and stratification for precision oncology.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full 4D Path company profile →

Constellation Pharmaceuticals

HQ: United States Website

Description: Provider of novel therapeutics in the emerging field of epigenetics, focusing on selective regulators of epigenetic function critical to controlling gene expression; the first biopharmaceutical company dedicated to this area.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Constellation Pharmaceuticals company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Rubicon Genomics

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Rubicon Genomics

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Rubicon Genomics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Rubicon Genomics's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Rubicon Genomics

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Rubicon Genomics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Rubicon Genomics's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Rubicon Genomics

4.2 - Public trading comparable groups for Rubicon Genomics

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Rubicon Genomics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Rubicon Genomics

What does Rubicon Genomics do?

Rubicon Genomics is a provider of advances in translating human genetics “laboratory knowledge” into practical medicine applications; founded in 2000 by University of Michigan faculty Dr. John Langmore and Dr. Vladimir Makarov, with roots in Michigan.

Who are Rubicon Genomics's competitors?

Rubicon Genomics's competitors and similar companies include Ginkgo Bioworks, Syros, Floragenex, 4D Path, and Constellation Pharmaceuticals.

Where is Rubicon Genomics headquartered?

Rubicon Genomics is headquartered in United States.

How many employees does Rubicon Genomics have?

Rubicon Genomics has 1,000 employees 🔒.

When was Rubicon Genomics founded?

Rubicon Genomics was founded in 2010 🔒.

What sector and industry vertical is Rubicon Genomics in?

Rubicon Genomics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Rubicon Genomics

Who are the top strategic acquirers in Rubicon Genomics's sector and industry

Top strategic M&A buyers and acquirers in Rubicon Genomics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Rubicon Genomics?

Top strategic M&A buyers groups and sectors for Rubicon Genomics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Rubicon Genomics's sector and industry vertical

Which are the top PE firms investing in Rubicon Genomics's sector and industry vertical?

Top PE firms investing in Rubicon Genomics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Rubicon Genomics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Rubicon Genomics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Rubicon Genomics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Rubicon Genomics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Rubicon Genomics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Rubicon Genomics?

The key public trading comparables and valuation benchmarks for Rubicon Genomics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Rubicon Genomics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Rubicon Genomics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Rubicon Genomics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Rubicon Genomics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Rubicon Genomics's' sector and industry vertical?

Access recent funding rounds and capital raises in Rubicon Genomics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Rubicon Genomics

Start Free Trial Book a Demo